Dermatophytosis
disease diseaseOn this page
Also known as dermatomycosisfungal skin diseasefungal skin diseasesringwormskin disease, fungalskin diseases, fungal
Summary
Dermatophytosis (MONDO:0004678) is a disease (an umbrella term covering 11 Mondo subtypes) with 74 GWAS associations across 40 studies and 5 clinical trials. Top therapeutic interventions include fluconazole, itraconazole, and hyoscyamine. A subtype of tinea infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 11 Mondo subtypes
- GWAS associations: 74
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dermatophytosis |
| Mondo ID | MONDO:0004678 |
| DOID | DOID:8913 |
| ICD-10-CM | B35 |
| ICD-11 | 1802307036 |
| NCIT | C26745 |
| SNOMED CT | 47382004 |
| UMLS | C0011636 |
| MedGen | 3768 |
| Is cancer (heuristic) | no |
Also known as: dermatomycosis · fungal skin disease · fungal skin diseases · ringworm · skin disease, fungal · skin diseases, fungal
Data availability: 74 GWAS associations (40 studies).
Disease family
This is a subtype of tinea infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › tinea infection › dermatophytosis
Related subtypes (8): otomycosis, conidiobolomycosis, cutaneous candidiasis, eumycotic mycetoma, pityriasis versicolor, tinea favosa, deep seated dermatophytosis, fungal infection of the toenail
Subtypes (11): tinea barbae, ectothrix infectious disease, endothrix infectious disease, dermatophytosis of groin and perianal area, tinea corporis, tinea unguium, tinea profunda, tinea manuum, dermatophytosis of scalp or beard, tinea pedis, Majocchi granuloma
Genetics & variants
GWAS landscape
74 GWAS associations across 40 studies. Top hits map to 28 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs7196726 | 7e-79 | ZNF646 | A | 1.07 |
| chr16:31083324 | 2e-39 | G | 0.07 | |
| rs17839568 | 1e-36 | PRSS53 | T | 0.06 |
| rs11864806 | 1e-36 | ZNF646, PRSS53 | G | 0.06 |
| rs1794269 | 1e-36 | HLA-DQB1 - MTCO3P1 | T | 1.05 |
| rs1421085 | 1e-35 | FTO | T | 0.06 |
| rs558269137 | 2e-27 | CCDST, FLG | CACTG | 0.8 |
| rs10094888 | 3e-24 | LYPD2 - LYNX1-SLURP2 | T | 1.04 |
| rs12123821 | 1e-18 | CCDST | C | 0.11 |
| chr16:31045852 | 1e-16 | CAA | 0.07 | |
| rs61816761 | 3e-16 | FLG, CCDST | G | 0.17 |
| rs10912488 | 3e-16 | SLC25A38P1 - AIMP1P2 | A | 1.03 |
| rs1829637 | 1e-15 | KRT77 | A | 1.03 |
| chr17:44096553 | 2e-15 | G | 0.05 | |
| rs2236506 | 9e-15 | RTEL1, RTEL1-TNFRSF6B | A | 0.97 |
| rs438735 | 1e-14 | ARRDC2 - RPS18P13 | A | 0.95 |
| rs612057 | 9e-14 | KNTC1 - HCAR2 | T | 1.03 |
| rs62066119 | 3e-13 | RPS26P8 - LINC02210 | T | 1.04 |
| rs848 | 6e-13 | IL13, TH2LCRR | A | 0.97 |
| rs4689388 | 1e-12 | JAKMIP1-DT - WFS1 | G | 0.04 |
| rs62106252 | 5e-12 | LINC01865 | G | 0.09 |
| rs55818528 | 6e-12 | LYNX1-SLURP2 - LY6D | T | 0.03 |
| rs73984689 | 8e-12 | KANSL1 | G | 0.04 |
| rs6425145 | 1e-11 | SLC25A38P1 - AIMP1P2 | T | 0.04 |
| chr1:8498680 | 2e-11 | A | 0.04 | |
| rs7903146 | 3e-11 | TCF7L2 | C | 0.03 |
| rs6577497 | 4e-11 | RERE | A | 1.02 |
| chr1:152312600 | 6e-11 | C | 0.18 | |
| chr8:142732775 | 2e-10 | G | 0.05 | |
| rs1885767 | 3e-10 | LINC01065 - PCDH8P1 | A | 1.02 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475560 | Verma A | 2024 | 97,617 | 302,401 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90475561 | Verma A | 2024 | 95,136 | 306,081 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477141 | Verma A | 2024 | 38,505 | 67,722 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479769 | Verma A | 2024 | 38,505 | 67,722 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477144 | Verma A | 2024 | 36,994 | 69,578 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479767 | Verma A | 2024 | 36,994 | 69,578 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90473080 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 30,117 | 428,323 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667807 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 30,117 | 428,323 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90809876 | Haapaniemi H | 2026 | 14,554 | 1,151,461 | The genetic basis of dermatophytosis skin infection susceptibility. |
| GCST90477139 | Verma A | 2024 | 14,214 | 38,346 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 8 |
| Tier 2: splice/UTR | 2 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 40 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 37 |
| low_freq (0.01-0.05) | 4 |
| rare (<0.01) | 0 |
| unknown | 9 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 19 |
| unknown | 10 |
| intergenic_variant | 10 |
| missense_variant | 6 |
| 3_prime_UTR_variant | 2 |
| frameshift_variant | 1 |
| stop_gained | 1 |
| non_coding_transcript_exon_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs7196726 | 16 | 31080754 | G>A | 0.413 | missense_variant | ZNF646 | 7e-79 | Tier 1: coding |
| chr16:31083324 | 0.385 | 2e-39 | Tier 4: intronic/intergenic | |||||
| rs17839568 | 16 | 31088462 | T>C | 0.429 | intron_variant | PRSS53 | 1e-36 | Tier 4: intronic/intergenic |
| rs11864806 | 16 | 31083883 | G>A,C,T | 0.429 | 3_prime_UTR_variant | ZNF646, PRSS53 | 1e-36 | Tier 2: splice/UTR |
| rs1794269 | 6 | 32706117 | C>G,T | 0.401 | intergenic_variant | HLA-DQB1 - MTCO3P1 | 1e-36 | Tier 4: intronic/intergenic |
| rs1421085 | 16 | 53767042 | T>C | 0.407 | intron_variant | FTO | 1e-35 | Tier 4: intronic/intergenic |
| rs558269137 | 1 | 152312601 | CACTG>C | 0.016 | frameshift_variant | CCDST, FLG | 2e-27 | Tier 1: coding |
| rs10094888 | 8 | 142762416 | C>T | 0.362 | intron_variant | LYPD2 - LYNX1-SLURP2 | 3e-24 | Tier 4: intronic/intergenic |
| rs12123821 | 1 | 152206676 | C>T | 0.047 | intron_variant | CCDST | 1e-18 | Tier 4: intronic/intergenic |
| chr16:31045852 | 1e-16 | Tier 4: intronic/intergenic | ||||||
| rs61816761 | 1 | 152313385 | G>A,C,T | 0.016 | stop_gained | FLG, CCDST | 3e-16 | Tier 1: coding |
| rs10912488 | 1 | 172877652 | A>G,T | 0.27 | intron_variant | SLC25A38P1 - AIMP1P2 | 3e-16 | Tier 4: intronic/intergenic |
| rs1829637 | 12 | 52695529 | G>A,C,T | 0.303 | intron_variant | KRT77 | 1e-15 | Tier 4: intronic/intergenic |
| chr17:44096553 | 0.217 | 2e-15 | Tier 4: intronic/intergenic | |||||
| rs2236506 | 20 | 63690302 | G>A | 0.215 | missense_variant | RTEL1, RTEL1-TNFRSF6B | 9e-15 | Tier 1: coding |
| rs438735 | 19 | 18015397 | C>A,G | 0.094 | intergenic_variant | ARRDC2 - RPS18P13 | 1e-14 | Tier 4: intronic/intergenic |
| rs612057 | 12 | 122700003 | T>C | 0.455 | intron_variant | KNTC1 - HCAR2 | 9e-14 | Tier 4: intronic/intergenic |
| rs62066119 | 17 | 45617831 | C>T | 0.189 | intergenic_variant | RPS26P8 - LINC02210 | 3e-13 | Tier 4: intronic/intergenic |
| rs848 | 5 | 132660808 | A>C,G,T | 0.295 | 3_prime_UTR_variant | IL13, TH2LCRR | 6e-13 | Tier 2: splice/UTR |
| rs4689388 | 4 | 6268329 | G>A | 0.414 | intergenic_variant | JAKMIP1-DT - WFS1 | 1e-12 | Tier 4: intronic/intergenic |
| rs62106252 | 2 | 408713 | G>A | 0.044 | intron_variant | LINC01865 | 5e-12 | Tier 4: intronic/intergenic |
| rs55818528 | 8 | 142780034 | T>C,G | 0.395 | intergenic_variant | LYNX1-SLURP2 - LY6D | 6e-12 | Tier 4: intronic/intergenic |
| rs73984689 | 17 | 46107038 | G>A | 0.185 | intron_variant | KANSL1 | 8e-12 | Tier 4: intronic/intergenic |
| rs6425145 | 1 | 172875269 | T>A,C,G | 0.31 | intron_variant | SLC25A38P1 - AIMP1P2 | 1e-11 | Tier 4: intronic/intergenic |
| chr1:8498680 | 0.321 | 2e-11 | Tier 4: intronic/intergenic | |||||
| rs7903146 | 10 | 112998590 | C>G,T | 0.289 | intron_variant | TCF7L2 | 3e-11 | Tier 4: intronic/intergenic |
| rs6577497 | 1 | 8545608 | A>G,T | 0.36 | intron_variant | RERE | 4e-11 | Tier 4: intronic/intergenic |
| chr1:152312600 | 6e-11 | Tier 4: intronic/intergenic | ||||||
| chr8:142732775 | 2e-10 | Tier 4: intronic/intergenic | ||||||
| rs1885767 | 13 | 53167993 | A>G | 0.398 | intron_variant | LINC01065 - PCDH8P1 | 3e-10 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07342153 | PHASE4 | RECRUITING | Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis |
| NCT03098615 | PHASE4 | COMPLETED | Study Evaluating the Effect of Jublia on Dermatophytomas |
| NCT00856596 | PHASE3 | UNKNOWN | Once a Day Topical Treatment for Athlete’s Foot Fungus Inbetween the Toes in Males and Females |
| NCT07270471 | Not specified | COMPLETED | Evaluation of Two Dermatophyte qPCR Kits on Skin and Keratinous Samples. |
| NCT07420894 | Not specified | COMPLETED | Comparison of Combination of Itraconazole and Isotretinoin Versus Itraconazole Alone in the Treatment of Resistant Trichophyton Infection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUCONAZOLE | 4 | 1 |
| ITRACONAZOLE | 4 | 1 |
| HYOSCYAMINE | -1 | 1 |
Related Atlas pages
- Drugs: Fluconazole, Itraconazole, Hyoscyamine